Form 4: Johnson & Johnson Executive John C. Reed Reports Stock Transactions

EVP John C. Reed of Johnson & Johnson reports the vesting of restricted share units and subsequent tax withholding.

Summary

• On May 1, 2024, John C. Reed, EVP of Innovative Medicine R&D at Johnson & Johnson, reported transactions involving common stock.
• 22,255 restricted share units vested and converted into common stock at a price of $0.00.
• Following this transaction, Reed directly owns 22,561 shares of common stock.
• 10,984 shares were withheld for payment of taxes upon the vesting of the restricted share units at a price of $144.59.
• After the tax withholding, Reed directly owns 11,577 shares of common stock.
• Reed also holds 53,510 restricted share units.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, as required by the SEC. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The transactions reported are typical for executives receiving stock-based compensation.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation.

Key Dates